fbpx

Nyheder

Lundbeckfonden Ventures nyheder

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two independent review committees completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Company’s Phase 2 open-label clinical...
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals Inc. a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868,...
Cambridge, UK and Indianapolis, US – 16 September 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 192,498 Ordinary Shares of...
Designation Underscores Urgent Need for New Antifungals Targeting Multidrug-Resistant Pathogens SAN DIEGO – Sept. 9, 2019 – Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral...
Cambridge, UK and Indianapolis, US – 5 September 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces its unaudited interim results for the six-month period ended 30 June 2019. A conference call will take place today at...
Lund, Sweden, 18:00 pm CET, 30 August 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids. During August, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 August 2019, the number of shares in BONESUPPORT HOLDING AB...
Lund, Sweden, 10.00 am CET, 21 August 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, announces that the patient enrollment schedule for the ongoing FORTIFY study is extended. Providing strong clinical evidence in support of its core technology, CERAMENT, is one of the cornerstones...
Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of...
Cambridge, UK and Indianapolis, US –  12 August 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, will issue its interim results for the six-month period ended 30 June 2019 on Thursday 5 September 2019. A conference call will...
1 2 3 4 5 61

Lundbeckfonden Ventures

Nyheder

BONESUPPORTTM CERTiFy STUDY ON CERAMENT ® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY
9. december 2019
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
25. november 2019
Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis
25. november 2019